KETAMINE SEDATION FOR ADULT BURN DRESSING CHANGES

SUMMARY
Ketamine is a nonbarbiturate anesthetic/analgesic agent which produces a “dissociative” effect as well as an analgesic effect. The use of ketamine as adjunctive or primary sedative/analgesic agent for dressing changes in adult burn patients may result in improved compliance with both the dressing change and accompanying physical and occupational therapy.

RECOMMENDATIONS

<table>
<thead>
<tr>
<th>Level</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 1</td>
<td>None</td>
</tr>
</tbody>
</table>
| Level 2 | Ketamine should be given with concurrent benzodiazepine therapy to minimize emergence reactions. Ketamine is contraindicated in patients with the following conditions:  
- History of or current myocardial ischemia or arrhythmias  
- Severe pulmonary secretions  
- Concurrent closed head injury  
- History of or current glaucoma  
- Psychiatric history |
| Level 3 | For patients with significant burn injuries, consider ketamine if adequate analgesia unable to be obtained. Recommend the following procedure:  
- Ketamine 0.5 mg/kg (or 50 mg max) IV bolus over 3-5 minutes  
- Then, initiate Ketamine 0.05 mg/kg/h infusion, titrate by 0.05 mg/kg/h increments to max 1 mg/kg/h to SAS 3-4 or RASS -1 to 0 during the dressing change, discontinue at the end of the dressing change  
- Midazolam 1-2 mg IV at induction and 0.5-2 mg IV at the conclusion of the procedure just prior to discontinuation of the ketamine infusion  
- Midazolam and fentanyl may be administered as needed during the procedure in addition to the ketamine per the Burn Service dressing change orders  
- Emergency equipment (BVM, oxygen, and suction) should be in the room during the dressing change |

INTRODUCTION
Burn patients undergo frequent extensive and painful dressing changes. As a result of undergoing multiple dressing changes, burn patients develop tolerance to both opioid and benzodiazepine agents.

EVIDENCE DEFINITIONS

| Class I | Prospective randomized controlled trial. |
| Class II | Prospective clinical study or retrospective analysis of reliable data. Includes observational, cohort, prevalence, or case control studies. |
| Class III | Retrospective study. Includes database or registry reviews, large series of case reports, expert opinion. |
| Technology assessment | A technology study which does not lend itself to classification in the above-mentioned format. Devices are evaluated in terms of their accuracy, reliability, therapeutic potential, or cost effectiveness. |

LEVEL OF RECOMMENDATION DEFINITIONS

| Level 1 | Convincingly justifiable based on available scientific information alone. Usually based on Class I data or strong Class II evidence if randomized testing is inappropriate. Conversely, low quality or contradictory Class I data may be insufficient to support a Level I recommendation. |
| Level 2 | Reasonably justifiable based on available scientific evidence and strongly supported by expert opinion. Usually supported by Class II data or a preponderance of Class III evidence. |
| Level 3 | Supported by available data, but scientific evidence is lacking. Generally supported by Class III data. Useful for educational purposes and in guiding future clinical research. |
Tolerance to the analgesic and sedative agents leads to increased doses in order to maintain adequate sedation and analgesia during the procedure. For patients with significant burns (>20% total body surface area) two problems emerge: 1) prolonged recovery after each dressing change due to high opioid and benzodiazepine doses and 2) heterotopic ossification as a result of pain-limited mobility. The addition of ketamine to a regimen of opioids and benzodiazepines for dressing changes may not only decrease the opioid and benzodiazepine requirements but also facilitate improved compliance with physical and occupational therapy leading to a decreased incidence of heterotopic ossification (1).

Ketamine is a nonbarbiturate anesthetic/analgesic agent which is structurally related to phencyclidine and cyclohexamine (2). Ketamine produces a “dissociative” anesthetic response (which prevents high brain centers from perceiving auditory, visual or painful stimuli) as well as analgesia (2). Ketamine’s effects are mediated through both opioid and non-opioid mechanisms. The use of anesthetic-level doses of ketamine results in a trancelike, cataleptic state without respiratory depression. The patient may be awake but is disconnected from their environment, immobile, and unresponsive to pain. Overall, ketamine results in sensory blockade with amnesia and analgesia (2). Other clinical effects of ketamine include elevated intraocular and intracranial pressure, cerebral vasodilatation, and bronchodilatation (2,3).

Ketamine exhibits a pharmacokinetic profile that makes it ideal for procedural sedation. It has a rapid onset of 30-40 seconds following IV administration. Duration is as short as 5-10 minutes after a single IV dose up to 30-45 minutes with repeat dosing. Recovery time following continuous infusion may be as long as an hour. No dosage adjustments are required for renal impairment but may require lower doses in hepatic insufficiency. Dosing for adult procedural sedation should include a bolus dose (administered by a physician) with either a supplemental bolus dose or a continuous infusion for the duration of the procedure. Suggested initial dosing: ketamine 0.5mg/kg IV over at least 1 minute followed by either a repeat in dose in 5-15 minutes or a continuous infusion of 5-20 mcg/kg/minute (2,5,6-9). Continuous infusion doses up to 45 mcg/kg/min have been described in the burn population (6). Patients who require repeat administration of ketamine may develop tolerance leading to increased doses (2,3,5).

There are multiple adverse effects associated with the administration of ketamine in adult patients. The most common adverse events include hypertension, tachycardia, and emergence reactions (characterized by vivid dreams, out-of-body experiences, floating sensations, hallucinations, delirium, confusion or "weird trips" which occur in up to 50% of adults receiving ketamine) (2-5). Skeletal muscle hyperactivity including twitching, extensor spasms, myoclonus, random extremity movements, fasciculations, and rigidity have also been described – these are more frequent at higher doses (2). Other common side effects include increased upper airway secretions, nystagmus and diplopia (2,3,5). The majority of the adverse events are mitigated by the concurrent use of benzodiazepines – especially midazolam (2).

LITERATURE REVIEW
[Class II] MacPherson RD, et.al. conducted a prospective study on the use of a combination ketamine/midazolam PCA for burn dressing changes. Each PCA contained ketamine 200mg/midazolam 10mg/20mL normal saline. The PCA was programmed to provide demand doses of ketamine 20mg/midazolam 0.5mg every three minutes; there was no basal rate. The PCA was controlled either by the patient or the nurse performing the dressing change. Other oral or intravenous opioid analgesics could be administered prior to the start of the dressing change only. 44 patients were evaluated during 95 procedures which lasted 78 ± 33 minutes and used a mean of 9 mL per procedure (~ketamine 180mg/midazolam 4.5mg). At the end of the procedure, patients and staff rated the effectiveness of the treatment on a scale of 1 to 10 (best) – with an average score of 8.5/10 for both patients and staff (calculated median = 9/10). Adverse events were noted in 15/44 patients with the most frequent being hallucinations (11/44) and desaturations < 95% (5/44). The authors concluded that this PCA provided adequate and effective analgesia (11).

[Class II] Newton A, et.al. conducted a prospective, observational study on the use of intravenous ketamine for procedural sedation in adult patients (age > 16 years). Patients were excluded if they had an abnormal airway, current respiratory infection, TBI, ocular injury, increased intraocular pressure, cardiac disease, psychotic illness, uncontrolled HTN, hyper- or hypothyroidism, porphyria, or an allergy to
ketamine. Patients received an initial dose of ketamine 0.5mg/kg IV which was repeated in 5 minutes if adequate sedation not achieved. Patients were on continuous ECG and pulse-oximetry and blood pressure was checked every 5 minutes. They enrolled 92 patients and achieved adequate sedation in 91 of the 92 patients (98.9%). Twenty of the 92 patients experienced adverse events, 12 of which were emergence-related reactions (12).

[Class III] Ward CM, et.al. evaluated ten adults (ages 24-74 years) who received ketamine as a part of their burn dressing change sedation. These patients were kept NPO for 4 hours prior to sedation. Ketamine (concentration ketamine 400mg / atropine 0.6mg) was administered by an anesthesiologist. Their protocol consisted of an induction dose of ketamine 2mg/kg IV followed by ketamine 4mg/kg IM. Subsequent IM doses of ketamine were administered when the patient made purposeful movements or nystagmus reappeared. A final dose of ketamine 1mg/kg was administered at the end of the dressing change. Ketamine was found to provide adequate analgesia (9).

[Class III] Demling RH, et.al. described the use of ketamine for anesthesia during tangential excision of burn eschar in the burn unit. They used a dose of ketamine 4mg/kg IM which provided adequate sedation and analgesia for approximately 20 minutes. A repeat dose was given if the patient started to emerge prior to completion of the procedure. For patients who underwent repeated procedures, doses as high as 6mg/kg IM were administered. Only 10% of their patients developed emergence reactions – all of which were mild (13).

[Class III] San Francisco General Hospital has developed a protocol for the use of ketamine during dressing changes in burn patients. Dosing of 0.5-1mg/kg IV for dressing changes can produce analgesia for 5-30 minutes. The protocol is described below (3):

- Emergency equipment should be immediately available (oxygen, suction and crash cart)
- Preferred route of administration is IM 2-3mg/kg with MD present during administration. IV administration by anesthesia or anesthesia resident only – 0.5-1mg/kg
- Contraindications: psychiatric history, h/o HTN, elderly patients, h/o MI, increased ICP or IOP, respiratory difficulties, eclampsia

[Class I] Yamauchi M, et.al. conducted a prospective, randomized study comparing the addition of ketamine or placebo to fentanyl for post-operative analgesia in patients undergoing cervical or lumbar spine surgery. Group 1: ketamine 1mg/kg bolus, then ketamine 42 mcg/kg/h x 24 hours. Group 2: ketamine 1mg/kg bolus, then ketamine 83mcg/kg/h x 24 hours. Group 3: placebo. All patients were placed on a fentanyl PCA and prescribed diclofenac 50mg suppositories every 8 hours as needed. 200 patients enrolled in the study. Patients with cervical spine surgery in Group 2 had significantly lower pain scores and were more satisfied with their post-operative pain control compared to Group 1 at 24 hours and compared to placebo at 48 hours. There were no differences in the lumbar spine surgery groups (10).

[Class I] Gűndüz M, et.al. conducted a prospective, randomized trial comparing the use of ketamine alone compared with ketamine + dexmedetomidine or ketamine + midazolam during dressing changes in burn patients for dressing changes in the operating room – non-intubated patients. Patients received placebo, dexmedetomidine (1 mcg/kg) or midazolam (0.05 mg/kg) 10min before ketamine 1 mg/kg IV bolus. An additional ketamine dose of 1mg/kg would be administered for visual-analog scale pain scores ≥ 5. There were no significant differences between the groups with respect to pain scores during & after the dressing change, duration of dressing change or recovery time after the dressing change. There was significantly more sedation in the ketamine + dexmedetomidine group. There was one episode of hypotension recorded in the ketamine + dexmedetomidine group and one patient in the ketamine only group developed hallucinations (16).

[Class II] Canpolat DG, et.al. conducted a prospective, randomized trial comparing the use of ketamine + propofol versus ketamine + dexmedetomidine during burn dressing changes in pediatric patients (ages 8-60 months). Patients received either propofol 1mg/kg or dexmedetomidine 0.5 mcg/kg and then ketamine 1 mg/kg. The propofol and dexmedetomidine could be redosed at the anesthesiologists’ discretion during the procedure; patients were not intubated. There was no significant difference with respect to the
duration of the procedure and recovery time. There were significantly more respiratory depression and hypoxia in the ketamine-propofol group compared to the ketamine-dexmedetomidine group (17).
<table>
<thead>
<tr>
<th>Study</th>
<th>No. of Patients (age range)</th>
<th>Route of Administration</th>
<th>Ketamine Dosing</th>
<th>Adjunctive Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edrich T, et al. (6)</td>
<td>1 (28y)</td>
<td>IV – continuous</td>
<td>Ketamine 2.7mg/kg/h IV infusion</td>
<td>IV morphine, versed, valium, propofol – all of which were weaned when ketamine started</td>
</tr>
<tr>
<td>Ward CM, et al. (8)</td>
<td>6 (age 9mon-8y)</td>
<td>IV IM</td>
<td>Ketamine 2mg/kg IV induction then Ketamine 4mg/kg IM (may repeat PRN) then Ketamine 1mg/kg IV at the end of the procedure</td>
<td>Ketamine/Atropine 400mg/0.6mg for induction</td>
</tr>
<tr>
<td>MacPherson RD, et al. (11)</td>
<td>49 (age 16-76y)</td>
<td>IV-PCA</td>
<td>Ketamine 10mg/Versed 0.5mg/mL per PCA 1 mL q3min (administered by patient or RN)</td>
<td>Pre-treat w/po or IV opioids only</td>
</tr>
<tr>
<td>Newton A, Fitton L. (12)</td>
<td>92 (age 16-89)</td>
<td>IV</td>
<td>Ketamine 0.5mg/kg IV then 0.5mg/kg IV q5min prn</td>
<td>No information provided</td>
</tr>
<tr>
<td>Demling RH, et al. (13)</td>
<td>45 (age 18mon-71y)</td>
<td>IM</td>
<td>Ketamine 4mg/kg IM x1 May repeat x1 if needed Max dose in study 6mg/kg IM</td>
<td>No information provided</td>
</tr>
<tr>
<td>Slogoff S, et al. (14) Burn dressing changes</td>
<td>40 (age 3-55y)</td>
<td>IM</td>
<td>Ketamine 1.5mg IM x 1 (average of 3.75 doses/patient)</td>
<td>No information provided</td>
</tr>
<tr>
<td>Sage M, et al. (15)</td>
<td>62 (age 11mon-10y)</td>
<td>IV – continuous</td>
<td>&lt; 35 kg Ketamine 10mg/kg IV induction (later changed to 4mg/kg) then 2mg/kg IV prn then 350-658 mcg/kg/min</td>
<td>&lt; 35 kg (premed) Trimeprazine 2mg/kg po Atropine 0.6mg po</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&gt; 35 kg Ketamine 2mg/kg IV induction, then 1mg/kg prn OR then ketamine 1mg/mL in D5W at 67-360 mcg/kg/min</td>
<td>&gt; 35 kg (premed) Pethidine (narcotic) Atropine Promethazine 25mg IV (age 16-65y)</td>
</tr>
<tr>
<td>Gündüz M, et al. (16) Burn dressing changes</td>
<td>90 (age 19-65y)</td>
<td>IV bolus</td>
<td>Group 1: ketamine 1mg/kg IV x1 Group 2: dexmedetomidine 1mcg/kg + ketamine 1mg/kg Group 3: midazolam 0.05mg/kg + ketamine 1mg/kg</td>
<td>May repeat Ketamine 1mg/kg for pain scores ≥ 5</td>
</tr>
<tr>
<td>Canpolat DG, et al. (17) Burn dressing changes</td>
<td>60 (age 8-60 mon)</td>
<td>IV bolus</td>
<td>Group 1: propofol 1mg/kg + ketamine 1mg/kg Group 2: dexmedetomidine 0.5mcg/kg + Ketamine 1mg/kg</td>
<td>May repeat propofol or dexmedetomidine</td>
</tr>
</tbody>
</table>
REFERENCES